Shares of biotechnology company Immutep (NASDAQ:IMMP) are soaring today after the combination of its eftilagimod and Merck’s (NYSE:MRK) Keytruda received fast-track status from the U.S. Food and Drug Administration (FDA) for the treatment of non-small cell lung cancer (NSCLC).
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Importantly, eftilagimod also provides a chemotherapy-free alternative for patients suffering from NSCLC as well.
Is Immutep Stock a Good Buy?
IMMP stock only has one analyst covering it, giving it a Moderate Buy rating based on one Buy. However, its price target of $8 still implies a massive 379.33% potential upside for the stock.
That’s after a nearly 58% slide in the price of IMMP stock over the past year.
